105214-48-0
Chemical Structure
Gypenoside LVI
- CAS No.: 105214-48-0
- Formula:C53H90O23
- Molecular Weight:1095.28
IUPAC Name: (2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5S,6R)-2-(((2R,3R,5R,8R,9R,10R,12R,13R,14R,17S)-2,12-dihydroxy-4,4,8,10,14-pentamethyl-17-((S)-6-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hept-5-en-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
InChIKey: SDPJKRBUXSIVOP-FMNOVIRCSA-N
SMILES: C[C@]12[C@@]([C@]3(C)[C@@](CC1)(C(C)(C)[C@@H](O[C@H]4[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](O)C3)[H])(C[C@@H](O)[C@]6([C@@]2(C)CC[C@@]6([C@@](O[C@@H]7O[C@H](CO[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@H](O)[C@H]7O)(CCC=C(C)C)C)[H])[H])[H]
Biological Activity: Gypenoside LVI is an orally active dammarane-type triterpenoid compound found in Gynostemma pentaphyllum. Gypenoside LVI inhibits ERK and JNK phosphorylation, the NLRP3 inflammasome, and modulates M1 to M2 microglial polarization. Gypenoside LVI downregulates PCSK9 expression through a SREBP-independent pathway. Gypenoside LVI promotes cholesterol efflux via ABCG1 and SRB1, upregulates LXRα-mediated reverse cholesterol transport, and attenuates foam cell formation by reducing lipid accumulation and cholesterol uptake. Gypenoside LVI inhibits IL-6 and IL-1β secretion, reduces oxidative stress, neuroinflammation, microglial and astrocyte activation, and inhibits LPS-induced microglial proliferation. Gypenoside LVI can be used for research on atherosclerosis, hypercholesterolemia, depression, and non-small cell lung cancer[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gypenoside LVI | Gypenoside LVI is an orally active dammarane-type triterpenoid compound found in Gynostemma pentaphyllum. Gypenoside LVI inhibits ERK and JNK phosphorylation, the NLRP3 inflammasome, and modulates M1 to M2 microglial polarization. Gypenoside LVI downregulates PCSK9 expression through a SREBP-independent pathway. Gypenoside LVI promotes cholesterol efflux via ABCG1 and SRB1, upregulates LXRα-mediated reverse cholesterol transport, and attenuates foam cell formation by reducing lipid accumulation and cholesterol uptake. Gypenoside LVI inhibits IL-6 and IL-1β secretion, reduces oxidative stress, neuroinflammation, microglial and astrocyte activation, and inhibits LPS-induced microglial proliferation. Gypenoside LVI can be used for research on atherosclerosis, hypercholesterolemia, depression, and non-small cell lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shen C‑Y, et al. Gypenoside LVI attenuates foam cell formation by promoting cholesterol export and inhibiting inflammation response. Journal of Functional Foods. 2018 Nov;50:71‑77.
- [2]. Wang J, et al. Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2021 Oct;91:153688.
- [3]. Guo M, et al. Gypenosides ameliorate depression by modulating microglial state transition via the NLRP3/Caspase-1/ASC signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2026 Jul;156:158189.
- [4]. Zhou P, et al. Chromosome-Level Genome Assembly of the Allotetraploid Gynostemma pentaphyllum Provides Novel Insights Into the Biosynthesis of Ginsenoside and Gypenoside LVI. Plant biotechnology journal. 2026 Jun;24(6):4204-4220.
- [5]. Chen DJ, et al. Metabolite profiling of gypenoside LVI in rat after oral and intravenous administration. Archives of pharmacal research. 2015 Jun;38(6):1157-67.
